{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:43:05Z","timestamp":1793835785428,"version":"4.6.1"},"reference-count":12,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"published-print":{"date-parts":[[2019,6,17]]},"abstract":"<jats:p> Background: The preferred ambulatory IV therapy for cellulitis is often once-daily cefazolin combined with once-daily oral probenecid (C+P). However, due to a national probenecid drug shortage in 2011, our centre developed a replacement protocol for the administration of cefazolin continuous infusion (CCI) using elastomeric infusers. Our goal was to compare treatment efficacy, duration of IV therapy, and recurrence associated with CCI and C+P using retrospective data from our centre. Methods: We conducted a non-inferiority single-centre retrospective cohort study of emergency department medical records. Patients received either C+P (cefazolin 2 g IV once daily plus probenecid 1 g PO once daily) or CCI (cefazolin 2 g IV loading dose, followed by cefazolin 6 g IV via continuous infusion over 24 hours, via an elastomeric infuser). We compared treatment efficacy, duration of IV therapy, and recurrence rates. Results: A\u00a0total of 203 patients were analyzed, with 107 included in the CCI arm and 96 in the C+P arm. Overall, CCI users and C+P users were comparable in their sociodemographic and clinical variables measured at admission. We observed increased odds of achieving successful treatment among the CCI group, however it did not reach statistical significance (odds ratio [OR] 2.25; 95% CI 0.84 to 6.07). Recurrence rates were similar between both groups (OR 1.91; 95% CI 0.32 to 11.31). The average duration of IV therapy was similar between groups ( p = 0.6). Conclusions: With results suggesting that CCI was non-inferior to C+P, and that both approaches required similar treatment durations, CCI could represent an acceptable alternative to C+P for the ambulatory IV treatment of cellulitis. <\/jats:p>","DOI":"10.3138\/jammi.2018-0039","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T18:07:51Z","timestamp":1560794871000},"page":"108-112","source":"Crossref","is-referenced-by-count":3,"title":["Continuous cefazolin infusion versus cefazolin plus probenecid for the ambulatory treatment of uncomplicated cellulitis: A\u00a0retrospective cohort study"],"prefix":"10.3138","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-2352","authenticated-orcid":true,"given":"Daniel L","family":"Landry","sequence":"first","affiliation":[{"name":"Pharmacy Department, Dr. Georges-L.-Dumont University Hospital Centre, Vitalit\u00e9 Health Network, Moncton, New Brunswick, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Eltonsy","sequence":"additional","affiliation":[{"name":"Centre de formation m\u00e9dicale Nouveau-Brunswick, Moncton, New Brunswick, Canada"},{"name":"Maritime Strategy for Patient Oriented Research SUPPORT Unit, Moncton, New Brunswick, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc P","family":"Jalbert","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Dr. Georges-L.-Dumont University Hospital Centre, Vitalit\u00e9 Health Network, Moncton, New Brunswick, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Girouard","sequence":"additional","affiliation":[{"name":"Microbiology & Infectious Diseases Department; Dr. Georges-L.-Dumont University Hospital Centre, Vitalit\u00e9 Health Network, Moncton, New Brunswick, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Couture","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Dr. Georges-L.-Dumont University Hospital Centre, Vitalit\u00e9 Health Network, Moncton, New Brunswick, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"B\u00e9langer","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Dr. Georges-L.-Dumont University Hospital Centre, Vitalit\u00e9 Health Network, Moncton, New Brunswick, Canada"},{"name":"Department of Family and Emergency Medicine, Universit\u00e9 de Sherbrooke, Sherbrooke, Qu\u00e9bec, Canada"},{"name":"Office of Research Services, Dr. Georges-L.-Dumont University Hospital Centre, Vitalit\u00e9 Health Network, Moncton, New Brunswick, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1696","reference":[{"issue":"14","key":"ir1","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/archinte.168.14.1585","volume":"168","author":"Hersh AL","year":"2008","journal-title":"Arch Intern Med."},{"issue":"3","key":"ir2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/jama.2016.8825","volume":"316","author":"Raff AB","year":"2016","journal-title":"JAMA"},{"key":"#cr-split#-ir3.1","unstructured":"3. NB Provincial Health Authorities Anti-Infective Stewardship Committee. Treatment of cellulitis\/skin infection-September 2017 [Internet]. Bathurst, NB: Vitalit\u00e9 Health Network [2017 Sep"},{"key":"#cr-split#-ir3.2","unstructured":"cited 2018 Mar\u00a01]. Available from: http:\/\/www.vitalitenb.ca\/en\/doctors\/treatment-guidelines\/antimicrobial-treatment-guidelines-common-infections-0."},{"issue":"2","key":"ir4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/ciu444","volume":"59","author":"Stevens DL","year":"2014","journal-title":"Clin Infect Dis."},{"issue":"3","key":"ir5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/AAC.10.3.395","volume":"10","author":"Thys JP","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ir6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/jac\/dkf129","volume":"50","author":"Howard GW","year":"2002","journal-title":"J Antimicrob Chemother."},{"issue":"3","key":"ir7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1128\/AAC.00389-08","volume":"53","author":"Zeller V","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"issue":"11","key":"ir8","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1086\/340056","volume":"34","author":"Grayson ML","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ir9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/600296","volume":"49","author":"Spellberg B","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ir10","first-page":"94","volume":"78","author":"Abdul-Aziz MH","year":"2012","journal-title":"Minerva Anestesiol"},{"issue":"6","key":"ir11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","volume":"194","author":"Roberts JA","year":"2016","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.3138\/jammi.2018-0039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T12:55:14Z","timestamp":1741870514000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.3138\/jammi.2018-0039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6,17]]}},"alternative-id":["10.3138\/jammi.2018-0039"],"URL":"https:\/\/doi.org\/10.3138\/jammi.2018-0039","relation":{},"ISSN":["2371-0888"],"issn-type":[{"value":"2371-0888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]}}}